Key Highlights
- 34.83% is the move in Cue Biopharma, Inc. (NASDAQ:CUE) in today's session on November 18, 2026, lifting the traded price to USD 3.81 from a calculated prior close of USD 2.83, a calculated USD 0.98 gain.
- 79.9% is the decline in Cue Biopharma, Inc. (NASDAQ:CUE) on November 17, 2026, from a USD 14.10 close on November 16 to USD 2.83, after third quarter results were released that afternoon.
- 50.0 million is the third quarter 2026 net loss in USD at Cue Biopharma, Inc. (NASDAQ:CUE), or USD 4.74 per share, against USD 7.4 million a year earlier, with USD 29.8 million of administrative costs mostly non-cash.
- 57.9 million is the cash and equivalents balance in USD at September 30, 2026, up from USD 27.1 million at December 31, 2025, with stockholders' Equity of USD 38.4 million.
What Moved Cue Biopharma, Inc. (NASDAQ:CUE) in Trading on November 18, 2026 (+USD 0.98, +34.83%)
The traded price of Cue Biopharma, Inc. (NASDAQ:CUE) in today's session on November 18, 2026 is USD 3.81, a move of +34.83% on Volume of 8.32M shares. On a calculated basis, the prior close was USD 2.83 (USD 3.81 divided by 1.3483) and the USD move is +USD 0.98 (price minus prior close). The shares opened 20.49% above the prior close, a calculated USD 3.41, and traded 11.73% above the open. Today's price remains about 73.0% below the USD 14.10 close of November 16, 2026 (calculated). Using the 10,561,814 weighted average shares of the third quarter, the indicative calculated value at USD 3.81 is about USD 40.2 million.
The Rationale: Rebound After the Post-Results Slide for Cue Biopharma, Inc. (NASDAQ:CUE)
No company release dated November 18, 2026 was identified in published coverage, so the move is read as a rebound after the volatile November 17, 2026 session. The company released third quarter 2026 results at 4:48 p.m. ET on November 16, 2026, and the release did not address the price action. Revenue was USD 0.1 million versus USD 2.1 million a year earlier, Research and Development rose to USD 17.0 million from USD 4.8 million, and administrative expense reached USD 29.8 million from USD 4.9 million. The CUE-221 anti-IgE Phase 2 study in chronic spontaneous urticaria met its primary endpoint, with 78% of high-IgE patients on 4 mg/kg reaching complete hive resolution at week 12 versus 0% on placebo.
Valuation, Liquidity and Risks for Cue Biopharma, Inc. (NASDAQ:CUE)
The latest reported period is the third quarter ended September 30, 2026. The net loss was USD 50.0 million, or USD 4.74 per share on 10,561,814 weighted shares, versus USD 7.4 million a year earlier. The nine month net loss was USD 208.3 million versus USD 28.2 million, including a USD 90.0 million loss on Warrant issuance. Cash of USD 57.9 million compares with a calculated USD 5.48 per weighted average share, above today's USD 3.81. A calculated value under USD 100 million brings small-cap, dilution and clinical-stage risks.
Where Things Stand
Cue Biopharma, Inc. (NASDAQ:CUE) traded at USD 3.81 today, November 18, 2026, up 34.83% from a calculated prior close of USD 2.83, on volume of 8.32M shares. That close was 79.9% below the USD 14.10 recorded on November 16, 2026. The third quarter release reported a net loss of USD 50.0 million and cash of USD 57.9 million but no explanation of the price move. Positive CUE-221 Phase 2 data frame the pipeline, while dilution and clinical uncertainty define the risk. Rebounds of this size can reverse quickly, and this article is not Investment advice.






Please wait processing your request...